KRAS and colorectal cancer: As PIK3CA mutations often coexist with KRAS and BRAF mutations in advanced cancers, including colorectal cancers [51], combination of AKT inhibition with panRAF inhibition are expected to induce at a minimum additive effects in both KRASmut/PIK3CAmut and BRAFmut/PIK3CAmut CRC models.